Existing lung scarring, known medically as pulmonary fibrosis, cannot be reversed by any treatment currently approved for clinical use. The two drugs available for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow the rate at which lung function declines but do not undo scar tissue that has already formed. That said, the picture is more nuanced than a flat “no.” Some forms of lung scarring, particularly those triggered by infections or removable environmental exposures, can partially resolve on their own. And several experimental therapies in early testing, including engineered immune cells and inhaled gene-silencing particles, have reversed fibrosis in animal models in ways that no current drug can match.
Why Lung Scars Are So Stubborn
When lung tissue is injured by infection, inhaled toxins, radiation, or unknown triggers (as in IPF), the body sends repair signals. Fibroblasts, the cells responsible for wound repair, transform into myofibroblasts that lay down collagen and other structural proteins. In a healthy repair process, these myofibroblasts finish their work and either die off or revert to a quieter state. In fibrosis, that off switch never flips. Signals like TGF-β1 keep driving myofibroblast activity long after the original injury is gone.1PubMed Central. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis
The resulting scar tissue is not just inert filler. As collagen accumulates, the lung stiffens, and that stiffness itself becomes part of the problem. Stiffened tissue activates more fibroblasts through mechanical sensing pathways, creating a feedforward loop: scarring makes the tissue rigid, and rigid tissue promotes more scarring.2PubMed Central. Extracellular Matrix Stiffness in Lung Health and Disease Specific proteins produced in response to this stiffness (such as CCN1 and CCN2) further amplify pro-fibrotic signaling, closing the loop even tighter.3iScience. Mechanobiology and the extracellular matrix in pulmonary fibrosis This self-reinforcing cycle is a major reason that simply removing the original cause of injury is often not enough to stop fibrosis once it has become established.
What Pirfenidone and Nintedanib Actually Do
The two drugs approved for IPF work through different mechanisms but achieve a similar practical result: they slow the disease rather than cure it. Pirfenidone damps down the exaggerated fibrotic response and has anti-inflammatory properties.4PubMed Central. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond Nintedanib blocks several growth-factor receptors that drive fibroblast proliferation and the secretion of scar-forming proteins like collagen and fibronectin.5PubMed Central. Novel Mechanisms for the Antifibrotic Action of Nintedanib In lab settings, nintedanib also inhibits the transformation of normal fibroblasts into the overactive myofibroblasts responsible for ongoing scarring.6PubMed. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis
In clinical practice, both drugs reduce the annual decline in forced vital capacity (FVC), the standard measure of how much air your lungs can push out. A meta-analysis covering multiple trials found that pirfenidone and nintedanib both significantly slowed FVC and gas-exchange decline over six and twelve months.7Vojnosanitetski pregled. Assessing the impact of nintedanib and pirfenidone on lung function in idiopathic pulmonary fibrosis: A comprehensive meta-analysis A study following pirfenidone patients found that the median annual FVC decline dropped from about 231 mL per year before treatment to roughly 49 mL per year at six months, with the benefit persisting through two years of follow-up. The effect was most dramatic in patients who had been losing lung function rapidly before starting the drug.8Scientific Reports. Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
Slowing decline is meaningful. It buys time, preserves quality of life, and can delay or prevent the need for a transplant. But it is not reversal. Patients on these drugs still have fibrotic lungs. And for people whose disease is progressing slowly, the measurable benefit may be harder to detect statistically, which makes treatment decisions more complicated.
When Scarring Can Improve on Its Own
Not all lung fibrosis behaves the same way. The cause matters enormously. IPF is a progressive, relentless disease with no known trigger removal that can halt it. But scarring caused by identifiable exposures sometimes follows a very different trajectory.
Hypersensitivity pneumonitis, for example, is triggered by repeated inhalation of specific allergens like mold, bird proteins, or certain chemicals. In its acute or subacute forms, removing the offending exposure is the central treatment strategy and can allow significant recovery.9PubMed Central. Hypersensitivity pneumonitis: a complex lung disease Chronic hypersensitivity pneumonitis with established scarring is harder to reverse, but even then, stopping exposure remains the most important step.
Post-viral scarring offers another instructive example. Data from survivors of the original 2003 SARS outbreak shows that most patients with fibrotic lung damage recovered within the first year and then stayed healthy, though about 20% showed significant fibrosis progression over the following five to ten years.10PubMed Central. Lung Fibrosis after COVID-19: Treatment Prospects The COVID-19 pandemic has raised similar concerns: post-COVID pulmonary fibrosis is one of the more severe long-term outcomes of infection.11PubMed Central. Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis Whether these cases will follow the SARS pattern, with most people recovering but a minority progressing, is still being tracked. Some researchers have documented lung impairments persisting up to three years after COVID recovery, with the SARS parallel suggesting that damage could linger for more than a decade in certain patients.12PubMed. Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis
The takeaway is that the question “can lung scarring be reversed” does not have a single answer across all causes. Scarring from a one-time insult like an infection has a meaningful chance of partial natural resolution. Progressive fibrotic diseases like IPF do not resolve spontaneously.
The Role of Cellular Aging in Fibrosis
One reason IPF is so resistant to reversal, and why it overwhelmingly strikes older adults, involves cellular senescence. Senescent cells are those that have stopped dividing but refuse to die. In the lungs of IPF patients, senescent epithelial cells in the alveoli (the tiny air sacs where gas exchange happens) drive a cascade of problems. They pile up alongside senescent fibroblasts, and together these cells keep pumping out signals that promote scar-tissue production.13PubMed Central. Cellular Senescence: The Trojan Horse in Chronic Lung Diseases
Recent research paints an even more detailed picture. Premature aging of alveolar stem cells suppresses the developmental programs that the lung would normally use to regenerate damaged tissue. Instead of producing functional new alveolar cells, the fibrotic lung accumulates dysfunctional “transitional” cells that fail to rebuild the air sacs and instead contribute further to scarring.14PubMed Central. Ageing-associated regenerative failure in the lung: stem cell senescence and transitional cell persistence in idiopathic pulmonary fibrosis Senescent fibroblasts simultaneously promote excessive collagen deposition, stiffen the surrounding tissue, and impair the ability of healthy epithelial cells to regenerate.15PubMed Central. Senescent fibroblasts in aging and pulmonary fibrosis So the aging process does not just make fibrosis more likely; it actively blocks the repair mechanisms that would be needed to reverse it.
Experimental Approaches Aiming for True Reversal
The limitations of pirfenidone and nintedanib have pushed researchers toward strategies that could actually undo established scarring rather than merely slow its accumulation. Several of these are in early stages but have produced striking results in animal models.
Engineered Immune Cells Targeting Scar-Producing Fibroblasts
One of the most exciting developments borrows technology from cancer therapy. CAR-T cells, immune cells genetically engineered to hunt specific targets, have been adapted to recognize and destroy activated fibroblasts that express a surface marker called fibroblast activation protein (FAP). Rather than extracting a patient’s cells, re-engineering them, and infusing them back (the standard and expensive route in cancer), researchers have developed lipid nanoparticles that can generate these CAR-T cells directly inside the body after injection.16PubMed Central. CAR T cell therapy for fighting IPF: perspectives on a living drug
In a mouse study using this approach, the in-vivo-generated CAR-T cells significantly reduced the population of FAP-positive fibroblasts. More remarkably, collagen content in treated lungs approached healthy levels, and the stiffness of the lung tissue dropped measurably. The researchers compared this head-to-head against pirfenidone and found that pirfenidone offered limited relief from fibrosis while the CAR-T approach produced significant improvement, including in aged mice.17Nature Communications. Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile This is still a long way from human trials, but it represents a genuine proof-of-concept that fibrosis reversal is biologically possible.
Senolytics
Given the role of senescent cells in driving fibrosis, drugs that selectively kill these cells (senolytics) are a logical therapeutic target. A combination of dasatinib and quercetin (often abbreviated DQ) reduced the burden of senescent cells in mouse lungs and restored function in a bleomycin-induced fibrosis model. A small first-in-human pilot study in IPF patients tested the safety and feasibility of DQ, though this was an early-stage trial focused on safety rather than measuring clinical reversal of fibrosis.18PubMed Central. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study The biological rationale is strong, but it remains to be seen whether clearing senescent cells translates to meaningful scar reversal in humans.
Inhaled Gene Silencing
A different tactic uses RNA interference (RNAi), a technique that silences specific genes after they have been activated. Researchers designed inhalable nanoparticles carrying small interfering RNA (siRNA) against IL-11, a signaling molecule that drives fibroblast activity. Delivered as an aerosol directly to the lungs of mice with established fibrosis, these nanoparticles reduced scar tissue and improved lung function without causing systemic side effects.19PubMed Central. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge Separate work has confirmed that sophisticated polymer carriers can deliver siRNA to human lung tissue and silence fibrosis-relevant gene targets like PAR2.20PubMed Central. Pulmonary siRNA Delivery with Sophisticated Amphiphilic Poly(Spermine Acrylamides) for the Treatment of Lung Fibrosis The appeal of inhaled delivery is obvious: the drug goes straight to the affected organ, potentially avoiding the gastrointestinal side effects that many patients experience with oral pirfenidone and nintedanib.
Stem Cell Therapy
Stem cells have been investigated for their ability to reduce inflammation, secrete anti-fibrotic factors, and potentially replace damaged lung cells. The proposed mechanisms are broad: dampening the immune overactivity that sustains fibrosis, promoting the growth of new blood vessels to support healing tissue, and differentiating into functional lung cells to replace dysfunctional ones.21PubMed Central. Pulmonary fibrosis: Is stem cell therapy the way forward? Stem cell approaches are still largely preclinical or in very early human trials for lung fibrosis, and the question of whether transplanted cells truly integrate into scarred lung tissue or simply exert their effects through secreted signals remains open.
Lung Transplant as the Last Option
For patients whose fibrosis has progressed to the point where breathing is severely impaired, lung transplantation remains the only intervention that eliminates the scarred tissue entirely. International guidelines recommend early referral for transplant evaluation in IPF because the disease’s course is unpredictable. Some patients remain stable for years; others deteriorate quickly, and acute flare-ups can occur without warning.22PubMed Central. Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
Transplant is not a simple solution. IPF patients tend to be older and to have other health conditions, including coronary artery disease and pulmonary hypertension, that complicate surgery. There is also an elevated risk of lung cancer in people with IPF, which requires careful screening before a patient can be listed for transplant. Organ availability, rejection risk, and the lifelong need for immunosuppressive drugs all factor in. But for patients with advanced disease and no other options, transplant offers a chance at substantially improved quality of life.
Tracking Fibrosis Without Waiting for Lung Function to Drop
One of the frustrations in treating lung fibrosis is that standard breathing tests only detect damage after a meaningful amount of lung function has already been lost. Researchers are working on better tools to catch changes earlier and to monitor whether a treatment is working.
Blood biomarkers are one promising avenue. A protein called KL-6 (Krebs von den Lungen-6), which is released by damaged alveolar cells, appears to predict disease progression. In a study of IPF patients, those with baseline KL-6 levels above a certain threshold were roughly two to three times more likely to experience disease progression.23PubMed Central. Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis Other circulating proteins are being evaluated for their ability to track response to nintedanib over time, with several showing increasing predictive value at the twelve-month mark, potentially offering more reliable thresholds for assessing whether fibrosis is progressing or stabilizing.24PubMed Central. Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study
On the imaging side, researchers have developed PET scan probes that bind directly to collagen in the lungs, lighting up areas of active fibrosis with much more specificity than a standard CT scan. In mouse models, one such probe showed two- to eight-fold greater uptake in fibrotic lungs compared to healthy ones.25Journal of Nuclear Medicine. Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis If this technology translates to humans, it could eventually allow clinicians to see whether a treatment is actually reducing collagen, not just holding lung function steady.
Genetic Susceptibility and What It Means for Treatment
Not everyone exposed to the same lung insults develops fibrosis, and genetic factors play a role in who does. A variant in the MUC5B gene promoter, which affects mucus production in the airways, has been linked to increased fibrosis risk. In studies of both IPF and chronic hypersensitivity pneumonitis, carrying the MUC5B risk variant was independently associated with a greater extent of scarring visible on imaging.26PubMed Central. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis
Telomere length, the protective caps on chromosomes that shorten with age and cell division, is another factor. Shorter telomeres have been correlated with more extensive honeycombing (a pattern of severe scarring) on lung CT scans in IPF patients.27Scientific Reports. The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort This connects to the senescence story discussed earlier: shorter telomeres push cells toward senescence faster, which in turn accelerates the regenerative failure that sustains fibrosis.
These genetic findings do not yet change day-to-day treatment decisions for most patients, but they point toward why some people’s fibrosis progresses faster than others and why age is such a strong risk factor. They also suggest that future therapies targeting senescence or telomere maintenance could, in theory, address a root cause rather than a downstream consequence.
How Lung Fibrosis Compares to Scarring in Other Organs
The lung’s resistance to scar reversal looks especially stark when compared with the liver, which has a much greater capacity for regeneration. Liver fibrosis and even early cirrhosis, once considered irreversible, are now understood to be at least partially reversible when the damaging stimulus is removed, for example by treating a hepatitis infection or stopping alcohol use.28PubMed Central. Reversal of liver fibrosis The liver has a unique regenerative toolkit: its cells can replicate and remodel scar tissue in ways that lung cells generally cannot.
The lung does have some capacity for fibrosis resolution. Inflammatory cells and enzymes can break down collagen, and myofibroblasts can undergo programmed cell death or revert to an inactive state.29PubMed Central. Mechanisms of Lung Fibrosis Resolution These resolution pathways do function in milder or earlier-stage fibrosis, which is likely why post-infection scarring can sometimes improve. But in IPF, the feedforward loop of stiffness, senescence, and sustained signaling overwhelms the lung’s limited repair capacity. The experimental therapies described above essentially try to tip the balance back toward resolution by removing the cells and signals that keep the loop running. Whether any of them will work well enough in humans to produce clinically meaningful reversal is the central unanswered question in the field right now.